Boston Advisors LLC Sells 35,112 Shares of Bruker Co. (NASDAQ:BRKR)

Boston Advisors LLC lessened its holdings in shares of Bruker Co. (NASDAQ:BRKR) by 59.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,796 shares of the medical research company’s stock after selling 35,112 shares during the quarter. Boston Advisors LLC’s holdings in Bruker were worth $1,045,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Advisory Services Network LLC purchased a new stake in Bruker in the second quarter worth $89,000. NumerixS Investment Technologies Inc grew its stake in Bruker by 153.2% in the second quarter. NumerixS Investment Technologies Inc now owns 2,532 shares of the medical research company’s stock worth $126,000 after purchasing an additional 1,532 shares during the period. Machina Capital S.A.S. purchased a new stake in Bruker in the second quarter worth $132,000. New York State Teachers Retirement System purchased a new stake in Bruker in the second quarter worth $150,000. Finally, HWG Holdings LP purchased a new stake in Bruker in the second quarter worth $172,000. Institutional investors own 66.63% of the company’s stock.

NASDAQ BRKR opened at $49.17 on Friday. Bruker Co. has a 12 month low of $26.10 and a 12 month high of $52.23. The stock has a market cap of $7.44 billion, a P/E ratio of 30.59, a P/E/G ratio of 2.37 and a beta of 1.36. The stock’s fifty day moving average price is $45.11 and its 200-day moving average price is $44.53. The company has a current ratio of 2.23, a quick ratio of 1.32 and a debt-to-equity ratio of 0.67.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, October 31st. The medical research company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.05. Bruker had a return on equity of 28.02% and a net margin of 10.20%. The firm had revenue of $521.10 million for the quarter, compared to analysts’ expectations of $493.52 million. During the same period in the prior year, the firm posted $0.37 earnings per share. The company’s quarterly revenue was up 11.7% on a year-over-year basis. As a group, analysts forecast that Bruker Co. will post 1.62 earnings per share for the current fiscal year.

In other news, Director Marc A. Kastner sold 3,203 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $47.39, for a total value of $151,790.17. Following the sale, the director now directly owns 7,608 shares of the company’s stock, valued at $360,543.12. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Mark Munch sold 47,203 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $42.87, for a total value of $2,023,592.61. Following the completion of the sale, the vice president now directly owns 96,063 shares in the company, valued at $4,118,220.81. The disclosure for this sale can be found here. Over the last three months, insiders sold 66,108 shares of company stock worth $2,849,941. Insiders own 26.50% of the company’s stock.

Several equities research analysts recently weighed in on the company. Stifel Nicolaus assumed coverage on Bruker in a research note on Thursday. They issued a “hold” rating on the stock. Bank of America raised Bruker from a “neutral” rating to a “buy” rating and set a $52.00 price target on the stock in a research note on Thursday, September 26th. Needham & Company LLC set a $58.00 price target on Bruker and gave the stock a “buy” rating in a research note on Friday, September 27th. BidaskClub cut Bruker from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Finally, Zacks Investment Research cut Bruker from a “hold” rating to a “sell” rating and set a $46.00 target price on the stock. in a research note on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $50.70.

Bruker Company Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Featured Article: Understanding each part of a balance sheet

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.